BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Real-time Euronext Amsterdam Other stock markets 03:40:13 10/05/2024 pm IST			5-day change	1st Jan Change
0.568 ^EUR	+1.43%		-7.79%	-47.41%

02/05	Benevolentai S.A. Announces Directorate Changes	CI
15/04	BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	CI

BenevolentAI : Benevolent AI, - Publication of the Revised Agenda for the 2024 AGM

April 17, 2024 at 01:04 pm IST

Benevolent AI

Benevolent AI

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date16 apr 2024 - 19:19

Statutory nameBenevolent AI

TitlePublication of the Revised Agenda for the 2024 AGM

Previous result

Next result

Related downloads

202404160000000020_BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24.pdf(opens in a new window)

202404160000000020_BenevolentAI Revised Agenda - 2024 AGM.pdf(opens in a new window)

Date last update: 17 April 2024

Attachments

Original Link
Permalink

Disclaimer

BenevolentAi SA published this content on 16 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2024 07:33:01 UTC.

Latest news about BenevolentAI

Benevolentai S.A. Announces Directorate Changes	02/05	CI
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	15/04	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	03/04	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	02/04	MT
Kenneth Mulvany Sends a Letter to Benovelent AI	02/04	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02/04	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	25/03	CI
BenevolentAI Announces Executive Changes	20/03	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member	24/01	CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer	24/01	CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO	22/01	AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	26/23/26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
BenevolentAI S.A. Announces Executive Changes	21/23/21	CI
BenevolentAI S.A. Announces Management Changes	21/23/21	CI
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery	20/23/20	DJ
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	20/23/20	MT
BenevolentAI Signs Strategic Collaboration with Merck	20/23/20	CI
BenevolentAI Appoints Chief Revenue Officer	18/23/18	MT
BenevolentAI Appoints Catherine Isted as Chief Financial Officer	11/23/11	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	31/23/31	CI
BenevolentAI Announces Retirement of Jackie Hunter as Non-Executive Director	21/23/21	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	05/23/05	CI
BenevolentAI Announces New Preclinical Data on Ai-Generated Target Identified in Their Ongoing Collaboration with Astrazeneca	31/23/31	CI

Chart BenevolentAI

Duration

Period

More charts

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Sector

Biotechnology & Medical Research

Calendar

24/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4822 GBP

Average target price

1.632 GBP

Spread / Average Target

+238.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-47.41%	73.58M
MODERNA, INC.	+23.37%	47.02B
LONZA GROUP AG	+49.45%	41.86B
IQVIA HOLDINGS INC.	-0.94%	41.76B
CELLTRION, INC.	-4.32%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B
BIO-TECHNE CORPORATION	+3.20%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+30.23%	12.34B

Other Biotechnology & Medical Research